Evidence map›Paper›PMID 41518443›Full record

ArticleApoptosis : an international journal on programmed cell death2026

A selenium-containing selective estrogen receptor modulator to overcome drug resistance of chronic myeloid leukemia.

Jing Liu, Chunmei Yang, Didi Gu, Ling Guo, Yan Zeng, Qulian Guo, You Yang, Qiuyu Meng, Jian Shu, Wenjun Liu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jing Liu *Department of Pediatrics, Children Hematological Oncology and Birth Defects Laboratory, Sichuan Clinical Research Center for Birth Defects, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.
Chunmei Yang *Department of Radiology, The Affiliated Hospital, Precision Imaging and Intelligent Analysis Key Laboratory of Luzhou, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Didi GuDepartment of Radiology, The Affiliated Hospital, Precision Imaging and Intelligent Analysis Key Laboratory of Luzhou, Southwest Medical University, Luzhou, 646000, Sichuan, China.
Ling GuoDepartment of Pediatrics, Children Hematological Oncology and Birth Defects Laboratory, Sichuan Clinical Research Center for Birth Defects, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.
Yan ZengDepartment of Pediatrics, Children Hematological Oncology and Birth Defects Laboratory, Sichuan Clinical Research Center for Birth Defects, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.
Qulian GuoDepartment of Pediatrics, Children Hematological Oncology and Birth Defects Laboratory, Sichuan Clinical Research Center for Birth Defects, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.
You YangDepartment of Pediatrics, Children Hematological Oncology and Birth Defects Laboratory, Sichuan Clinical Research Center for Birth Defects, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China.
Qiuyu MengKey Laboratory of Pollution Exposure and Health Intervention of Zhejiang Province, Interdisciplinary Research Academy (IRA), Zhejiang Shuren University, Hangzhou, 310015, China. qiuyumeng@zjsru.edu.cn.
Jian ShuDepartment of Radiology, The Affiliated Hospital, Precision Imaging and Intelligent Analysis Key Laboratory of Luzhou, Southwest Medical University, Luzhou, 646000, Sichuan, China. shujiannc@163.com.
Wenjun LiuDepartment of Pediatrics, Children Hematological Oncology and Birth Defects Laboratory, Sichuan Clinical Research Center for Birth Defects, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, Sichuan, China. wenjun_liu@swmu.edu.cn.
Lu YangDepartment of Radiology, The Affiliated Hospital, Precision Imaging and Intelligent Analysis Key Laboratory of Luzhou, Southwest Medical University, Luzhou, 646000, Sichuan, China. yanglu@swmu.edu.cn.

Funding

National Natural Science Foundation of China 81903460National Natural Science Foundation of China 82304311the Sichuan Medical Association Program Q2024004
6 · The paper itself

Abstract

Chemotherapy failure caused by adriamycin (ADM) and imatinib (IM) resistance remains a critical challenge in the treatment of chronic myeloid leukemia (CML). In this study, a novel compound 4, 4’-(selenophene-2, 5-diyl)bis(3-fluorophenol) (Se-1) with estrogen receptor regulation and selenium anticancer activity was applied to reverse drug resistance of CML. Se-1 exhibited superior inhibitory activity against resistant K562/ADM cells compared to sensitive K562 cells. The growth of K562/ADM in xenograft mouse was suppressed by Se-1 treatment. The anti-leukemia mechanism of Se-1 was tested by western-blot, flow cytometry, molecular docking and fluorescence imaging. The apoptosis rate was increasing after Se-1 treatment, meanwhile proteins of Cleaved PARP and Cleaved Caspase3 were up-regulated and Bcl-2 was down-regulated. In addition, the autophagy was activated through increasing of autophagy vesicles and proteins of LC3-II and P62, and inactivating of mTOR protein. Moreover, estrogen receptor α (ERα), ERK and P38 were activated, the proteins of PI3K and AKT1 were decreased. Overall, Se-1 exerted anti-CML effects through multi-mechanism interaction, which was expected to advance the research in reversing ADM and IM resistance of chronic myeloid leukemia.

Indexed as

Antineoplastic AgentsDrug Resistance, NeoplasmLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSelective Estrogen Receptor ModulatorsSeleniumAnimalsApoptosisAutophagyDoxorubicinEstrogen Receptor alphaFemaleHumansImatinib MesylateK562 CellsMiceXenograft Model Antitumor AssaysAntineoplastic AgentsDoxorubicinEstrogen Receptor alphaImatinib MesylateSelective Estrogen Receptor ModulatorsSeleniumAdriamycin and imatinib resistanceApoptosisAutophagyChronic myeloid leukemiaEstrogen receptors

Identifiers

PMID41518443

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.